CALI calcimedica.com: Forward P/S Multiple
CalciMedica, Inc. (CALI) ensures resilience through ESG standards and bioethics in immune pathology research. The company's expected P/S ratio confirms the trend of market valuations, where 0.00 shows the current volume of the metric. Growth potential is based on the supply of medications to hospitals for the treatment of pancreatitis. The startup is currently in the clinical development stage, which temporarily limits current revenue.
Summary analytical data breakdowns for CalciMedica (CALI)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Capital CalciMedica, Inc.|CALI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital calcimedica.com|CALI - Company Total Debt Obligations|Debt to Book Capitalization Ratio CalciMedica Inc|CALI - Company Long-Term Liabilities|Company Short-Term Debts CalciMedica|Quick Ratio calcimedica.com
- financial results and valuation multiples details:
CALI - Company Profit|Projected Future Earnings CalciMedica, Inc.|CALI - Business Payback Period|Forward P/E Multiple CalciMedica, Inc.|CALI - Price/Earnings to Growth Multiple|EV/EBITDA Multiple CalciMedica|CALI - Operating profit EBITDA|Net earnings per share for the last 12 months CalciMedica|CALI - Earnings per share for the trailing year|Quarterly EPS earnings growth calcimedica.com|CALI - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year CalciMedica, Inc.
- total revenue and sales volume data:
Comprehensive company analysis:CALI (CalciMedica)
The forward P/S measures the market value of CalciMedica, Inc. (CALI) relative to its expected revenue, allowing investors to assess the extent to which the asset is overpriced relative to its potential. By analyzing the projected P/S of the business on the GURU.Markets platform, one can determine the stability of the position of a company whose capitalization depends directly on the success of joint research in the field of acute organ inflammation therapy.
Competitors of CalciMedica, Inc. (CALI)
Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (Intrexon)|Forward Price-to-Revenue Multiple PHAR (Pharming)|NKTR (Nektar) - Forward Price to Sales|Forward P/S Multiple UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Future Price to Revenue|IMNM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Gossamer Bio Inc GOSS|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna Pharma|PVLA (Pieris Corp) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SVRA|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple AnaptysBio Corp ANAB|Astria Therapeutics Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio enGene Holdings Inc. (ENGN)|RAPT Therapeutics Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aerovate Therapeutics, Inc.|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|KYTX: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Tiziana Life Sciences|Cabaletta Bio, Inc (CABA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple VTYX (Ventyx Biosciences)|Market Cap to Expected Sales Ratio theratech.com|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc.)|Forward P/S Multiple Eledon Pharmaceuticals Inc. ELDN|AGEN: Forward Price-to-Revenue Multiple|Forward Price to Sales CLYM (Climb Bio, Inc)|ZURA: Forward P/S Multiple|aTyr Pharma, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Adagene Inc.|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Forward Price-to-Revenue Multiple Equillium Bio EQ|Price-to-Projected Revenue Ratio Connect Biopharma CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA - Price-to-Projected Revenue Ratio|InflaRx NV (IFRX) - Forward Price-to-Revenue Multiple|XFOR (X4 Pharmaceuticals Inc.) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Adicet Bio Inc. (ACET)|Price-to-Projected Revenue Ratio celularity.com|Forward Price-to-Revenue Multiple inmunebio.com (INMB)|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics PLC (BRNS)|Market Cap to Expected Sales Ratio Kezar Life Sciences Inc.|SAB Biotherapeutics, Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Akari Therapeutics, Plc (AKTX)|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales QTTB (q32bio.com)|GeoVax Labs Inc (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Edesa|Price-to-Projected Revenue Ratio iBio, Inc.|Forward Price-to-Revenue Multiple carismatx.com (CARM)|Forward P/S Multiple XTLB|Forward Price-to-Revenue Multiple Bolt Bio BOLT|Forward P/S Multiple HCWB (HCW Biologics)|APVO: Market Cap to Projected Revenue|AIM - Price-to-Projected Revenue Ratio|ADTX - Forward P/S Multiple|GRI Bio (GRI) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple XORTX Therapeutics|Price-to-Projected Revenue Ratio Vyome Therapeutics|Market Cap to Projected Revenue REVB (Revelation Biosciences, Inc.)|Forward P/S Multiple INDP|Forward Price-to-Revenue Multiple Scinai Immunotherapeutics SCNI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com
